ARTICLE | Clinical News
Purified poloxamer 188: Phase III started
February 11, 2013 8:00 AM UTC
Adventrx began the double-blind, placebo-controlled Phase III EPIC trial to evaluate 100 mg/kg IV ANX-188 for 1 hour followed by 30 mg/kg for up to 48 hours in 388 patients ages 8-17 years who have si...